Government-Owned Inventions; Availability for Licensing, 14138-14139 [E9-6933]
Download as PDF
<![CDATA[
14138
Federal Register / Vol. 74, No. 59 / Monday, March 30, 2009 / Notices
Types of respondents
Estimated
number of respondents
Estimated
number of responses per
respondent
Average burden hours per
response
Estimated total
annual burden
hours requested
Researchers, Physicians, Other Health Care Providers, Librarians, Students, General Public ...................................................................................
27,910
1
.129
3,607
The annualized cost to respondents
for each year of the generic clearance is
estimated to be $23,126. There are no
Capital Costs, Operating Costs, and/or
Maintenance Costs to report.
Request for Comments: Written
comments and/or suggestions from the
public and affected agencies should
address one or more of the following
points: (1) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the function of the agency, including
whether the information will have
practical utility; (2) Evaluate the
accuracy of the agency’s estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(3) Enhance the quality, utility, and
clarity of the information to be
collected; and (4) Minimize the burden
of the collection of information on those
who are to respond, including the use
of appropriate automated, electronic,
mechanical, or other technological
collection techniques or other forms of
information technology.
FOR FURTHER INFORMATION CONTACT: To
request more information on the
proposed project or to obtain a copy of
the data collection plans and
instruments, contact: David Sharlip,
National Library of Medicine, Building
38A, Room B2N12, 8600 Rockville Pike,
Bethesda, MD 20894, or call non-toll
free number 301–402–9680 or E-mail
your request to sharlipd@mail.nih.gov.
Comments Due Date: Comments
regarding this information collection are
best assured of having their full effect if
received within 60 days of the date of
this publication.
Dated: March 23, 2009.
Betsy L. Humphreys, M.L.S.,
Deputy Director, National Library of
Medicine, National Institutes of Health.
[FR Doc. E9–6934 Filed 3–27–09; 8:45 am]
sroberts on PROD1PC70 with NOTICES
BILLING CODE 4140–01–P
VerDate Nov<24>2008
18:33 Mar 27, 2009
Jkt 217001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
Federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Method of Making a Vaccine
Description of Technology: Current
invention describes the methods to
prepare vaccines, and to use such
vaccines in the vaccination and
treatment of human disease, e.g., the
human immunodeficiency virus (HIV)
infections and cancer. More specifically,
the present invention provides a vaccine
and method for making same which is
effective to elicit a desired antibody
against a target antigen comprising a
primary immunogen and a secondary
immunogen, wherein the primary
immunogen is effective to elicit B cell
receptors (BCRs) that are on the
maturational pathway of the desired
antibody and have an intermediate
degree of somatic mutational diversity,
and the secondary immunogen
comprises an epitope of the desired
target antibody and is effective to
further diversify the BCRs sufficient to
form mature BCRs having the identical
PO 00000
Frm 00034
Fmt 4703
Sfmt 4703
or substantially identical sequence as
the desired antibody.
Applications: Treatment and
prevention of HIV infection.
Advantages: Novel methods to design
vaccines for HIV treatment and
prevention; May also be used for
designing vaccines for cancer treatment.
Development Status: In vitro data
available.
Market: HIV therapeutics and
preventatives.
Inventor: Dimiter S. Dimitrov (NCI).
Publications:
1. MY Zhang, Y Shu, S Phogat, X
Xiao, F Cham, P Bouma, A Choudhary,
YR Feng, I Sanz, S Rybak, CC Broder,
GV Quinnan, T Evans, DS Dimitrov.
Broadly cross-reactive HIV neutralizing
human monoclonal antibody Fab
selected by sequential antigen panning
of a phage display library. J Immunol
Methods. 2003 Dec;283(1–2):17–25.
2. MY Zhang, X Xiao, IA Sidorov, V
Choudhry, F Cham, PF Zhang, P Bouma,
M Zwick, A Choudhary, DC Montefiori,
CC Broder, DR Burton, GV Quinnan Jr,
DS Dimitrov. Identification and
characterization of a new cross-reactive
human immunodeficiency virus type 1neutralizing human monoclonal
antibody. J Virol. 2004 Sep;78(17):9233–
9242.
3. Z Zhu, AS Dimitrov, KN Bossart, G
Crameri, KA Bishop, V Choudhry, BA
Mungall, YR Feng, A Choudhary, MY
Zhang, Y Feng, LF Wang, X Xiao, BT
Eaton, CC Broder, DS Dimitrov. Potent
neutralization of Hendra and Nipah
viruses by human monoclonal
antibodies. J Virol. 2006 Jan;80(2):891–
899.
4. MY Zhang, V Choudhry, IA
Sidorov, V Tenev, BK Vu, A Choudhary,
H Lu, GM Stiegler, HW Katinger, S
Jiang, CC Broder, DS Dimitrov. Selection
of a novel gp41-specific HIV-l
neutralizing human antibody by
competitive antigen panning. J Immunol
Methods. 2006 Dec 20;317(1–2):21–30.
5. V Choudhry, MY Zhang, IA
Sidorov, JM Louis, I Harris, AS
Dimitrov, P Bouma, F Cham, A
Choudhary, SM Rybak, T Fouts, DA
Montefiori, CC Broder, GV Quinnan Jr,
DS Dimitrov. Cross-reactive HIV–1
neutralizing monoclonal antibodies
selected by screening of an immune
human phage library against an
envelope glycoprotein (gpI40) isolated
E:\FR\FM\30MRN1.SGM
30MRN1
Federal Register / Vol. 74, No. 59 / Monday, March 30, 2009 / Notices
from a patient (R2) with broadly HIV-l
neutralizing antibodies. Virology. 2007
Jun 20;363(1):79–90.
6. Z Zhu, S Chakraborti, Y He, A
Roberts, T Sheahan, X Xiao, LE Hensley,
P Prabakaran, B Rockx, IA Sidorov, D
Corti, L Vogel, Y Feng, JO Kim, LF
Wang, R Baric, A Lanzavecchia, KM
Curtis, GJ Nabel, K Subbarao, S Jiang,
DS Dimitrov. Potent cross-reactive
neutralization of SARS coronavirus
isolates by human monoclonal
antibodies. Proc Natl Acad Sci USA.
2007 Jul 17;104(29):12123–12128.
7. Z Zhu, KN Bossart, KA Bishop, G
Crameri, AS Dimitrov, JA McEachern, Y
Feng, D Middleton, LF Wang, CC
Broder, DS Dimitrov. Exceptionally
potent cross-reactive neutralization of
Nipah and Hendra viruses by a human
monoclonal antibody. J Infect Dis. 2008
Mar 15;197(6):846–853.
8. MY Zhang, BK Vu, A Choudhary,
H Lu, M Humbert, H Ong, M Alam, RM
Ruprecht, G Quinnan, S Jiang, DC
Montefiori, JR Mascola, CC Broder, BF
Haynes, DS Dimitrov. Cross-reactive
human immunodeficiency virus type 1neutralizing human monoclonal
antibody which recognizes a novel
conformational epitope on gp41 and
lacks reactivity against self antigens. J
Virol. 2008 Jul;82(14):6869–6879.
Patent Status: U.S. Provisional
Application No. 61/104,706 filed 11 Oct
2008 (HHS Reference No. E–322–2008/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Sally Hu, Ph.D.;
301–435–5606; HuS@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute is seeking
statements of capability or interest from
parties interested in collaborative
research to further develop, evaluate, or
commercialize this method. Please
contact John D. Hewes, Ph.D. at 301–
435–3121 or hewesj@mail.nih.gov for
more information.
sroberts on PROD1PC70 with NOTICES
Anti-Hepatitis C Virus Activity of the
Protein Scytovirin (SVN)
Description of Technology: The
invention provides compositions and
methods of use for potent anti-HCV
protein scytovirin to prevent and treat
HCV infections. Currently there is
neither effective treatment nor vaccine
against HCV infection and chronic HCV
infection may lead to liver cancer and
death. Scytovirin can be used alone or
in combination with other anti-HCV
drugs for HCV treatment and
prevention.
Applications: The treatment and
prevention of HCV infections.
VerDate Nov<24>2008
18:33 Mar 27, 2009
Jkt 217001
Advantages: Potent anti-HCV activity;
Can be applied both systematically or
locally.
Development Status: In vitro data
available.
Market: HCV therapeutics and
preventatives.
Inventors: Barry R. O’Keefe et al.
(NCI).
Publications: Data collection and
manuscripts may be submitted in 2009.
Patent Status: U.S. Provisional
Application No. 61/137,511 filed 31 Jul
2008 (HHS Reference No. E–161–2008/
0–US–01).
Related Technology: HHS Reference
No. E–017–2002/0—Scytovirins and
Related Conjugates, Antibodies,
Compositions, Nucleic Acids, Vectors,
Host Cells, Methods of Production and
Methods of Using Scytovirin.
Licensing Status: Available for
licensing.
Licensing Contact: Sally Hu, Ph.D.;
301–435–5606, HuS@mail.nih.gov.
Collaborative Research Opportunity:
The National Cancer Institute CCR
Molecular Targets Development
Program is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize this technology. Please
contact John D. Hewes, Ph.D. at 301–
435–3121 or hewesj@mail.nih.gov for
more information.
Dated: March 19, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. E9–6933 Filed 3–27–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY: National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
SUMMARY: The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 207 to achieve expeditious
commercialization of results of
Federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
PO 00000
Frm 00035
Fmt 4703
Sfmt 4703
14139
ADDRESSES: Licensing information and
copies of the U.S. patent applications
listed below may be obtained by writing
to the indicated licensing contact at the
Office of Technology Transfer, National
Institutes of Health, 6011 Executive
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
Treatment of Schistosomiasis Using
Substituted Oxadiazole 2-Oxides
Description of Technology: Available
for licensing and commercial
development are pharmaceutical
compositions and methods for the
treatment of schistosomiasis in
mammals. The various compositions are
based on a number of compounds
derived from 1,2,5-oxadiazole that are
potent inhibitors of thioredoxin
glutathione reductase (TGR), a critical
parasite redox protein.
Schistosomiasis is a chronic disease
caused by trematode flatworms of the
genus Schistosoma, including S.
mansoni, S. japonicum and S.
haematobium. Adult schistosome
parasites live in an aerobic environment
within human hosts, and therefore must
have effective mechanisms to maintain
cellular redox balance. Additionally, the
worms must be able to evade reactive
oxygen species generated by the host’s
immune response. In most eukaryotes
there are two major systems to detoxify
reactive oxygen species, one based on
the tripeptide glutathione and the other
based on the protein thioredoxin.
Glutathione reductase (GR) reduces
glutathione disulfide, whereas
thioredoxin reductases (TrxR) are
pivotal in the Trx-dependent system. It
was recently discovered that specialized
TrxR and GR enzymes are absent in
schistosomes. Instead, they are replaced
by the unique multifunctional enzyme
TGR. This reliance on a single enzyme
for both glutathione disulfide and
thioredoxin reduction suggests that the
parasite’s redox systems are subject to a
bottleneck dependence on TGR, and
that TGR represents a potentially
important drug target.
Schistosomiasis remains a major and
neglected health problem in many
tropical areas. The health burden
resulting from schistosomiasis is
estimated to include more than 200
million people infected, 779 million at
risk of infection, 280,000 deaths
annually, and more than 20 million
individuals experiencing high
morbidity. Clinical manifestations of
schistosomiasis infection include
abdominal pain, cough, diarrhea,
E:\FR\FM\30MRN1.SGM
30MRN1
]]>Agencies
[Federal Register Volume 74, Number 59 (Monday, March 30, 2009)]
[Notices]
[Pages 14138-14139]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-6933]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, Public Health Service, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The inventions listed below are owned by an agency of the U.S.
Government and are available for licensing in the U.S. in accordance
with 35 U.S.C. 207 to achieve expeditious commercialization of results
of Federally-funded research and development. Foreign patent
applications are filed on selected inventions to extend market coverage
for companies and may also be available for licensing.
ADDRESSES: Licensing information and copies of the U.S. patent
applications listed below may be obtained by writing to the indicated
licensing contact at the Office of Technology Transfer, National
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville,
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A
signed Confidential Disclosure Agreement will be required to receive
copies of the patent applications.
Method of Making a Vaccine
Description of Technology: Current invention describes the methods
to prepare vaccines, and to use such vaccines in the vaccination and
treatment of human disease, e.g., the human immunodeficiency virus
(HIV) infections and cancer. More specifically, the present invention
provides a vaccine and method for making same which is effective to
elicit a desired antibody against a target antigen comprising a primary
immunogen and a secondary immunogen, wherein the primary immunogen is
effective to elicit B cell receptors (BCRs) that are on the
maturational pathway of the desired antibody and have an intermediate
degree of somatic mutational diversity, and the secondary immunogen
comprises an epitope of the desired target antibody and is effective to
further diversify the BCRs sufficient to form mature BCRs having the
identical or substantially identical sequence as the desired antibody.
Applications: Treatment and prevention of HIV infection.
Advantages: Novel methods to design vaccines for HIV treatment and
prevention; May also be used for designing vaccines for cancer
treatment.
Development Status: In vitro data available.
Market: HIV therapeutics and preventatives.
Inventor: Dimiter S. Dimitrov (NCI).
Publications:
1. MY Zhang, Y Shu, S Phogat, X Xiao, F Cham, P Bouma, A Choudhary,
YR Feng, I Sanz, S Rybak, CC Broder, GV Quinnan, T Evans, DS Dimitrov.
Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab
selected by sequential antigen panning of a phage display library. J
Immunol Methods. 2003 Dec;283(1-2):17-25.
2. MY Zhang, X Xiao, IA Sidorov, V Choudhry, F Cham, PF Zhang, P
Bouma, M Zwick, A Choudhary, DC Montefiori, CC Broder, DR Burton, GV
Quinnan Jr, DS Dimitrov. Identification and characterization of a new
cross-reactive human immunodeficiency virus type 1-neutralizing human
monoclonal antibody. J Virol. 2004 Sep;78(17):9233-9242.
3. Z Zhu, AS Dimitrov, KN Bossart, G Crameri, KA Bishop, V
Choudhry, BA Mungall, YR Feng, A Choudhary, MY Zhang, Y Feng, LF Wang,
X Xiao, BT Eaton, CC Broder, DS Dimitrov. Potent neutralization of
Hendra and Nipah viruses by human monoclonal antibodies. J Virol. 2006
Jan;80(2):891-899.
4. MY Zhang, V Choudhry, IA Sidorov, V Tenev, BK Vu, A Choudhary, H
Lu, GM Stiegler, HW Katinger, S Jiang, CC Broder, DS Dimitrov.
Selection of a novel gp41-specific HIV-l neutralizing human antibody by
competitive antigen panning. J Immunol Methods. 2006 Dec 20;317(1-
2):21-30.
5. V Choudhry, MY Zhang, IA Sidorov, JM Louis, I Harris, AS
Dimitrov, P Bouma, F Cham, A Choudhary, SM Rybak, T Fouts, DA
Montefiori, CC Broder, GV Quinnan Jr, DS Dimitrov. Cross-reactive HIV-1
neutralizing monoclonal antibodies selected by screening of an immune
human phage library against an envelope glycoprotein (gpI40) isolated
[[Page 14139]]
from a patient (R2) with broadly HIV-l neutralizing antibodies.
Virology. 2007 Jun 20;363(1):79-90.
6. Z Zhu, S Chakraborti, Y He, A Roberts, T Sheahan, X Xiao, LE
Hensley, P Prabakaran, B Rockx, IA Sidorov, D Corti, L Vogel, Y Feng,
JO Kim, LF Wang, R Baric, A Lanzavecchia, KM Curtis, GJ Nabel, K
Subbarao, S Jiang, DS Dimitrov. Potent cross-reactive neutralization of
SARS coronavirus isolates by human monoclonal antibodies. Proc Natl
Acad Sci USA. 2007 Jul 17;104(29):12123-12128.
7. Z Zhu, KN Bossart, KA Bishop, G Crameri, AS Dimitrov, JA
McEachern, Y Feng, D Middleton, LF Wang, CC Broder, DS Dimitrov.
Exceptionally potent cross-reactive neutralization of Nipah and Hendra
viruses by a human monoclonal antibody. J Infect Dis. 2008 Mar
15;197(6):846-853.
8. MY Zhang, BK Vu, A Choudhary, H Lu, M Humbert, H Ong, M Alam, RM
Ruprecht, G Quinnan, S Jiang, DC Montefiori, JR Mascola, CC Broder, BF
Haynes, DS Dimitrov. Cross-reactive human immunodeficiency virus type
1-neutralizing human monoclonal antibody which recognizes a novel
conformational epitope on gp41 and lacks reactivity against self
antigens. J Virol. 2008 Jul;82(14):6869-6879.
Patent Status: U.S. Provisional Application No. 61/104,706 filed 11
Oct 2008 (HHS Reference No. E-322-2008/0-US-01).
Licensing Status: Available for licensing.
Licensing Contact: Sally Hu, Ph.D.; 301-435-5606; HuS@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
is seeking statements of capability or interest from parties interested
in collaborative research to further develop, evaluate, or
commercialize this method. Please contact John D. Hewes, Ph.D. at 301-
435-3121 or hewesj@mail.nih.gov for more information.
Anti-Hepatitis C Virus Activity of the Protein Scytovirin (SVN)
Description of Technology: The invention provides compositions and
methods of use for potent anti-HCV protein scytovirin to prevent and
treat HCV infections. Currently there is neither effective treatment
nor vaccine against HCV infection and chronic HCV infection may lead to
liver cancer and death. Scytovirin can be used alone or in combination
with other anti-HCV drugs for HCV treatment and prevention.
Applications: The treatment and prevention of HCV infections.
Advantages: Potent anti-HCV activity; Can be applied both
systematically or locally.
Development Status: In vitro data available.
Market: HCV therapeutics and preventatives.
Inventors: Barry R. O'Keefe et al. (NCI).
Publications: Data collection and manuscripts may be submitted in
2009.
Patent Status: U.S. Provisional Application No. 61/137,511 filed 31
Jul 2008 (HHS Reference No. E-161-2008/0-US-01).
Related Technology: HHS Reference No. E-017-2002/0--Scytovirins and
Related Conjugates, Antibodies, Compositions, Nucleic Acids, Vectors,
Host Cells, Methods of Production and Methods of Using Scytovirin.
Licensing Status: Available for licensing.
Licensing Contact: Sally Hu, Ph.D.; 301-435-5606, HuS@mail.nih.gov.
Collaborative Research Opportunity: The National Cancer Institute
CCR Molecular Targets Development Program is seeking statements of
capability or interest from parties interested in collaborative
research to further develop, evaluate, or commercialize this
technology. Please contact John D. Hewes, Ph.D. at 301-435-3121 or
hewesj@mail.nih.gov for more information.
Dated: March 19, 2009.
Richard U. Rodriguez,
Director, Division of Technology Development and Transfer, Office of
Technology Transfer, National Institutes of Health.
[FR Doc. E9-6933 Filed 3-27-09; 8:45 am]
BILLING CODE 4140-01-P
